Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

Executive Summary

The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.

You may also be interested in...



Cirius’ Mixed Phase IIb Results In NASH Don’t Quell Its Enthusiasm For Phase III

Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.

Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits

Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.

Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel